TauRx achieves milestone in global Phase 3 clinical trials of LMTX™ for Alzheimer's Disease

Sep 19 - 2013 10:33 PM
Over 300 patients now enrolled worldwide in clinical trials for a second?generation tau aggregation inhibitor (TAI) aimed at halting the progression of Alzheimer’s
Read more

In Toronto, Two International Leaders Share One Goal: Slow or Halt the Progression of Alzheimer’s Disease with the Launch of Phase 3 Clinical Trials

Jun 11 - 2013 09:53 PM
Professor Claude Wischik, Executive Chairman of TauRx Therapeutics and Dr. Sharon Cohen, Medical Director of the Toronto Memory Program Announce the Canadian Launch of Pivotal Alzheimer’s Research
Read more

First UK patients enroll in Phase 3 clinical trials of LMTX™ for Alzheimer’s Disease

May 22 - 2013 01:00 PM
Clinical trials get under way in the UK with a second?generation tau aggregation inhibitor (TAI) aimed at halting the progression of Alzheimer’s
Read more

TauRx Chairman Highlights Future Consequences of Alzheimer’s in Asia

Apr 22 - 2013 02:00 PM
Demographic and societal impact of Alzheimer’s in China will grow exponentially if its current course is not averted, according to pioneer in tau pathology, a hallmark of Alzheimer’s Disease A new treatment targeting tau pathology is tomorrow’s hope for a brighter future, and Phase 3 clinical studies are bringing us closer to that goal.
Read more

TauRx Pharmaceuticals Receives $10.5m Follow-On Investment

Mar 04 - 2013 06:00 AM
Dundee Corporation maintains 5% stake in company developing a revolutionary treatment for Alzheimer’s Disease.
Read more